Table 3. Treatment for EBV-associated malignancies.
EBV-specific T cell activator | T cell source | Disease | CR, PR, remission, or disease free | References |
---|---|---|---|---|
LCL | Transplant donor derived | Post-HSCT PTLD | 11/13 | Rooney et al., 1995, 1998; Heslop et al., 1996, 2010 |
10/14 | Doubrovina et al., 2012 | |||
1/1 | Lucas et al., 1998 | |||
3/4 | Comoli et al., 2007 | |||
Allogeneic | Post-HSCT PTLD | 4/5 | Doubrovina et al., 2012 | |
Post-HSCT viremia or EBV-LPD | 9/10 | Naik et al., 2016 | ||
Post-SOT PTLD | 15/31 | Haque et al., 2007 | ||
Autologous | Post-SOT PTLD | 1/1 | Khanna et al., 1999 | |
Viral Ags from EBV, CMV, and ADV | Transplant donor derived | Post-HSCT PTLD | 2/2 | Naik et al., 2016 |
Allogeneic | Post-HSCT viremia or EBV-LPD | 1/2 | Naik et al., 2016 | |
APCs transduced with ADV vector encoding LMP1 and/or LMP2 | Autologous or third party | Active EBV+ lymphoma; EBV+ lymphoma (in remission) | 13/21; 27/29 | Bollard et al., 2014 |
Abbreviations used: ADV, adenovirus; CR, complete response; LPD, lymphoproliferative disease; PR, partial response.